Cargando…

2494. Real-World Use of Ibalizumab in Physician Office Infusion Centers (POICs)

BACKGROUND: Ibalizumab-uiyk (IBA) was recently approved for the treatment of multi-drug-resistant HIV-1 infection in patients (pts) failing other antiretroviral regimens. Clinical trial data demonstrated a decrease in HIV-1 viral load in 83% and 43% of patients (n = 40) receiving IBA for 2 and 25 we...

Descripción completa

Detalles Bibliográficos
Autores principales: Prokesch, Richard C, Schroeder, Claudia P, Hardin, Thomas C, Van Anglen, Lucinda J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809768/
http://dx.doi.org/10.1093/ofid/ofz360.2172